EUCTR2006-007089-12-IT进行中（未招募）不适用
iposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women - ND
GOIM GRUPPO ONCOLOGICO MERIDIONALE0 个研究点开始时间: 2007年5月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Breast cancer istologically assured, age>70 years old, validity state (WHO)< o = 2, desease at IV stage with one misurable unidimensionally lesion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous chemoteraphy for metastatic desease, concomitant serious deseases(cardiovascular, renal, hepatic,etc.), cardiopathy pre-existing with cardiac insufficiency
研究者
相似试验
进行中（未招募）
不适用
Panitumumab and Pegylated Liposomal Doxorubicin to Platinum-Resistant Epithelial Ovarian Cancer with KRAS Wild-type - AGO 22 - PaLiDoPlatinum-Resistant Epithelial Ovarian Cancer with KRAS Wild-typeMedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerEUCTR2008-007799-13-ATVejle Hospital33
进行中（未招募）
1 期
Pembrolizumab and trastuzumab in combination with chemotherapy before and after surgery for patients with HER2-positive gastric cancer - PHERFLOT –HER2 positive, localized esophagogastric adenocarcinomaMedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10066896Term: HER2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-006512-87-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH30
已完成
2 期
Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor support for elderly patients with advanced non-small cell lung cancer: A multicenter prospective single arm phase II study: DRAGON study(WJOG9416L)JPRN-UMIN000030598West Japan Oncology Group54
已完成
2 期
Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor support for elderly patients with advanced non-small cell lung cancer: A multicenter prospective single arm phase II study (WJOG9416L)non-small cell lung cancerNon-small cell lung cancerJPRN-jRCTs051180232Hata Akito65
进行中（未招募）
1 期
DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trialMedDRA version: 21.1Level: PTClassification code 10035226Term: Plasma cell myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2016-000433-51-GRniversity Medical Center Hamburg-Eppendorf36